Sooma launches direct-to-patient brain stimulation therapy for depression and chronic pain in Finland and Germany
Sooma Medical, a world-leading provider of safe and effective brain stimulation treatments for psychiatric and neurological disorders, launches a groundbreaking new model for treating depression and chronic pain. With this launch, Sooma is making its clinically proven brain stimulation therapy directly accessible to individuals in Finland and Germany, removing the need for doctor referrals and lengthy treatment queues in depression treatment.
Sooma is leading the global fight against depression by offering a flexible and accessible treatment solution through its portable neuromodulation device. The device, worn as a cap, uses tDCS therapy, a non-invasive technique using mild electrical currents to stimulate the brain and alleviate depression symptoms without the need for pharmaceuticals.
The treatment is clinically proven to be safe and effective and has been used by more than 30,000 patients in both primary and specialized healthcare in several European countries for over a decade. In direct response to strained healthcare resources and increasing waiting times, the new direct-to-consumer model provides faster and easier access to care.
“Healthcare systems and treatment waiting times are reaching a breaking point in many countries, including Finland and Germany. Untreated depression creates a significant burden for both individuals and society. With this new model, we are breaking down barriers to care and delivering effective depression treatment to those who currently have no timely access through traditional healthcare channels,” says Dr. Andreas Hartlep, CEO of Sooma.
In the new model, the treatment can be ordered directly online from Sooma, with no referral or active treatment relationship required to begin. The therapy is administered safely and conveniently at home, with Sooma providing comprehensive guidance on both the use of the device and progress monitoring. For those already receiving care, the treatment can also be integrated into an existing treatment plan, allowing the individual’s own doctor to oversee and track the therapy.
Sooma’s brain stimulation treatment provides an effective solution for treating depression, particularly for patients who haven’t responded to antidepressants. The treatment is safe and easy to use, without the serious or systemic side effects typically caused by antidepressants, and has no adverse medication interactions or risk of dependence. It can be used as a standalone treatment or in combination with other treatment types.
Sooma’s brain stimulation devices have become the most prescribed tDCS therapies worldwide, treating over 30,000 patients and in more than 250 clinics in 35 countries. Sooma has also gained notable industry recognition. In March 2025, Sooma received approval from the FDA to start a clinical trial in the US. Sooma was also the first device manufacturer to receive EU MDR certification for a tDCS device.
About Sooma Medical
Founded in 2013, Sooma is a Finnish medical device company specializing in non-invasive brain stimulation devices for neurological and psychiatric disorders. Sooma works closely with leading medical experts to develop effective treatment solutions. Developed in Finland, Sooma’s devices adhere to strict ISO 13485 and MDSAP quality management standards. To date, more than 30,000 patients have found relief with these treatments. Sooma Depression Therapy is available in more than 35 countries worldwide. In September 2023, Sooma became the first tDCS device manufacturer to receive EU MDR certification for medical devices.
soomamedical.com
Sooma Press kit
Latest news
Sooma closes 2025 with major milestones in improved access to better depression and pain care globally
Read more
FDA approved tDCS for at-home depression treatment
Read more
Science round-up webinar: tDCS in Depression and Chronic Pain – Clinical Advancements 2025
Read more